Selected Grants
DCA08 HS235-003
Clinical TrialPrincipal Investigator · Awarded by 35Pharma Inc. · 2025 - 2035SRD-001-1001
Clinical TrialPrincipal Investigator · Awarded by Sardocor Corp. · 2024 - 2032Safety and Efficacy of the Alleviant No-Implant Interatrial Shunt in Patients with Heart Failure and Reduced Ejection Fraction
Clinical TrialCo Investigator · Awarded by Alleviant Medical, Inc. · 2025 - 2032Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having Heart Failure with Preserved Ejection Fraction: Randomized Controlled Feasibility Trial
Clinical TrialPrincipal Investigator · Awarded by Axon Therapies, Inc. · 2024 - 2030ALLAY-HF
Clinical TrialCo-Principal Investigator · Awarded by Alleviant Medical, Inc. · 2023 - 2030A Prospective, Multi-Center, Open Label, Randomized Control Clinical Trial Evaluating the Safety and Efficacy of the Cordella Pulmonary Artery Sensor System in New York Heart Association (NYHA) Class II Heart Failure Patients (PROACTIVE-HF-2 Trial)
Clinical TrialPrincipal Investigator · Awarded by Endotronix, Inc. · 2024 - 2029Splanchnic Nerve Modulation In Heart Failure (Splanchnic X)
ResearchPrincipal Investigator · Awarded by National Heart, Lung, and Blood Institute · 2024 - 2029A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared with Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca AB · 2025 - 2029A Phase 1b, Pilot Trial Evaluating the Safety and Pharmacodynamic Effects of SRD-001 (AAV1-SERCA2a) in Subjects with Heart Failure with Preserved Ejection Fraction
Clinical TrialPrincipal Investigator · Awarded by Sardocor Corp. · 2023 - 2028Fluid management of Acute decompensated heart failure Subjects Treated with Reprieve System II
Clinical TrialPrincipal Investigator · Awarded by Reprieve Cardiovascular, Inc. · 2025 - 20281/2 Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction Extension Trial
ResearchCo Investigator · Awarded by National Institutes of Health · 2024 - 2028Hermes - HF
Clinical TrialPrincipal Investigator · Awarded by Novo Nordisk, Inc. · 2024 - 2028Probing Regional Metabolism During Exercise through Coronary Sinus Sampling
ResearchCo Investigator · Awarded by National Heart, Lung, and Blood Institute · 2025 - 2027Physical Rehabilitation for Older Patients with Acute HFpEF-The REHAB-HFpEF Trial - Site Per Patient
Clinical TrialPrincipal Investigator · Awarded by Wake Forest University Health Sciences · 2023 - 2027Physical Rehabilitation for Older Patients with Acute HFpEF-The REHAB-HFpEF Trial - Site Administration
Clinical TrialPrincipal Investigator · Awarded by Wake Forest University Health Sciences · 2023 - 2027A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction(PH-HFpEF); LEVEL:LEVosimendan to Improve Exercise Limitation in Pa
Clinical TrialPrincipal Investigator · Awarded by Tenax Therapeutics, Inc. · 2024 - 2027Fire1
Clinical TrialPrincipal Investigator · Awarded by Foundry Innovation & Research 1, Ltd. (FIRE1) · 2023 - 2027Home-based subcutaneous furosemide for decompensated heart failure
ResearchPrincipal Investigator · Awarded by scPharmaceuticals · 2025 - 2027Tectonic TX000045-003 (PH-HFpEF)
Clinical TrialPrincipal Investigator · Awarded by Tectonic Therapeutic · 2025 - 2026RECOVER-AUTO
Clinical TrialPrincipal Investigator · Awarded by DCRI-Duke-Site · 2023 - 2026Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
Clinical TrialPrincipal Investigator · Awarded by Procyrion, Inc. · 2023 - 2026Pulmonary Artery DenerVation Clinical Study using the Gradient Denervation System in Heart Failure Patients with Pulmonary Hypertension Group 2 (PreVail-PH2 Study)
Clinical TrialPrincipal Investigator · Awarded by Gradient Denervation Technologies · 2024 - 2026A Phase 2A, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986435/MYK-224 in Participants with Heart Failure with Preserved Ejection Fraction HFpEF
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2025 - 2026Digital Stethoscope for Detecting Pulmonary HTN
Clinical TrialPrincipal Investigator · Awarded by Eko Health, Inc. · 2025 - 2026Prediction and Prevention of Hepatic Decompensation in Patients with Cirrhosis
Clinical TrialCollaborator · Awarded by National Institute of Diabetes and Digestive and Kidney Diseases · 2021 - 2026Transforming Urine Output Tracking in Hospitalized Heart Failure Patients
ResearchCo Investigator · Awarded by National Heart, Lung, and Blood Institute · 2024 - 2026Role of the Splanchnic Vascular Compartment in Heart Failure with Preserved Ejection Fraction
ResearchPrincipal Investigator · Awarded by Doris Duke Charitable Foundation, Inc. · 2022 - 2026Duke Advanced HF Educational Meetings
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by Alleviant Medical, Inc. · 2025 - 2025Poseidon
ResearchPrincipal Investigator · Awarded by Novo Nordisk A/S · 2024 - 2025SEISMIC-HF II Clinical Validation Study
ResearchPrincipal Investigator · Awarded by Cardiosense, Inc. · 2025 - 2025SPIRRIT - HFpEF 2024 - 1/2 Clinical Coordinating Center for the Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction Study (SPIRRIT-EX)
ResearchPrincipal Investigator · Awarded by DCRI-Duke-Site · 2024 - 2025Center for Advancing Point of Care Technologies (CAPCaT) in HLBS Disorders.
ResearchPrincipal Investigator · Awarded by Daxor Corporation · 2024 - 2025Hemodynamics Core Study
ResearchPrincipal Investigator · Awarded by Cardiosense, Inc. · 2023 - 2025Fluid management of Acute decompensated heart failure subjects treated with reprieve decongestion management system (DMS) - FASTR Trial
Clinical TrialPrincipal Investigator · Awarded by Reprieve Cardiovascular, Inc. · 2023 - 2025IMAGING CORE LABORATORY: HEMODYNAMICS CORE FOR ACORAI MLG
ResearchPrincipal Investigator · Awarded by Acorai AB · 2023 - 2024An acute porcine model for Cardiac-Synchronized Diaphragmatic Stimulation as a novel extra-cardiac intervention for symptomatic chronic heart failure
ResearchCollaborator · Awarded by VisCardia, Inc. · 2022 - 2024CONFIDENT-HFpEF Phase 1
ResearchPrincipal Investigator · Awarded by Owkin, Inc. · 2023 - 2023SOLENOID PHASE 1
ResearchPrincipal Investigator · Awarded by Owkin, Inc. · 2023 - 2023Cardiac Filling Pressure Estimation with a Non-Invasive Device (Pufferfish)
Clinical TrialPrincipal Investigator · Awarded by Verily Life Sciences, LLC · 2022 - 2023Is Heart Failure with Preserved Edection Fraction the Symptomatic Manifestation of Liver Disease
ResearchPrincipal Investigator · Awarded by American Heart Association · 2021 - 2022Digoxin Toxicity Study
Clinical TrialPrincipal Investigator · Awarded by BTG International Inc · 2021 - 2022Congestion Phenotypes and Splanchnic Nerve Modulation in Chronic Heart Failure
Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 2020 - 2022Splanchnic Nerve Block for Therapy of Acute Heart Failure (Splanchnic HF)
Clinical TrialPrincipal Investigator · Awarded by American Heart Association · 2017 - 2019External Relationships
- 35 Pharma
- ADI
- Abbott Laboratories
- Acorai
- Ajax
- Akros
- Alio
- Alleviant Medical
- Artha
- Astellas Pharma Inc.
- Audicor
- Axon Therapies
- Berlin Heals
- Bioventrix
- Bodiguide
- Bodyport
- Boehringer Ingleheim
- Boston Scientific Corporation
- Bristol-Myers Squibb (BMS)
- Broadview Ventures
- CVRx
- Cadence
- Cardiosense, Inc
- Cardiostory
- Chugai Pharmaceutical (Roche Holding)
- Clinical accelerator
- Corstasis
- Daxor
- EKO Inc
- Echosens
- Endotronix
- Feldschuh Foundation
- Fire1
- FutureCardia
- Gradient
- Hatteras Investment Partners, LLC
- Heka Heart
- HemodynamIQ
- ISHI
- Impulse Dynamics
- Lexicon Pharmaceuticals, Inc.
- Maxwell Biomedical
- Medtronic
- Ni-Medical
- Novo Nordisk
- Nucleus Rx
- Orchestra
- Paragate
- Parasym
- Pharmacosmos
- PreHealth
- Procyreon
- Proton Intelligence
- Puzzle Medical
- ReCor
- Reprieve Cardiovascular Inc.
- Respicardia
- Restore Medical
- SC Pharma
- Scirent
- Shifamed
- Splendo Health Duke startup
- Summacor
- SutroSam
- SyMap
- Tricav
- Vasa
- Vascular Dynamics
- Vironix
- Viscardia
- Zoll
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.